iOmx Therapeutics AG
iOmx is a biopharmaceutical company focused on developing first-in-class cancer immune-therapeutics addressing novel immune checkpoints highjacked by cancer cells. Based on its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing its early-stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies.
iOmx Therapeutics at a glance:
| Field of Activity | iOmx develops first-in-class immune-oncology drug candidates targeting novel cancer immune evasion mechanisms. |
| Ownership Structure and Financing | iOmx is funded by an international consortium of leading life science investors: Wellington Partners; Sofinnova Partners; M Ventures; MIG Capital; and Athos Biopharma. |
| Technology | In order to discover druggable vulnerabilities in immunosuppressive tumors, iOmx Therapeutics efficiently applies its proprietary iOTarg™ target discovery platform, a systematic high-throughput genetic screening approach, to identify and validate novel immune checkpoint targets in cancer models that fail to respond to current cancer immunotherapies. |
| Products/Services | The company’s lead product candidate, OMX-0407, is a first-in-class oral SIK3 inhibitor sensitizing tumor cells to the effect of immunederived tumor necrosis factor (TNF) in the tumor microenvironment. The kinase inhibitor demonstrated promising therapeutic efficacy as single agent as well as in combination with anti-PD-1 therapy in multiple preclinical studies and will enter the clinic by end of 2022. |
| Unique Selling Point | iOTarg™, the company’s platform technology, can screen and identify novel checkpoint modulators directly on tumor samples, with the aim of unveiling organ-specific tumor evasion strategies and developing cancer immunotherapies with monotherapy potential. |
| Date of Incorporation/ Number of Employees |
2016/36 |
Contact:
| Address | Fraunhoferstr. 13 82152 Martinsried |
| Telephone | +49-89-8999-7090-0 |
| info@iomx.com | |
| Web Address | www.iomx.com |
| Social Media |
ARTIKEL ZU DIESEN SCHLAGWORTEN
- Carbios : "Wir stellen uns einer der größten Herausforderungen unserer Zeit”
- HMNC Brain Health mit Finanzierung über 14,3 Mio. EUR
- Dr. Matthias Kromayer: „Ich erwarte gute Lebenszeichen von der Branche“
- Hohe Investitionen in den Healthcare-Markt
- Echtzeit-Messung von Bioprozessen
- Wenn die Verunsicherung endlich ein Ende haben könnte
- Forbion: Final Closing des Forbion IV bei 360 Mio. EUR
- Pierre Fabre startet Biopharma-Fonds
- 2015 was a record year for biopharma